E2511

Phase 1Small molecule

Eisai

E2511 is one of 39 small molecule programs targeting Alzheimer's Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer's DiseaseNot yet recruiting

Alzheimer's DiseasePhase 1

Not yet recruiting

Competition

Competitive Landscape

59 competitors in Alzheimer's Disease

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

31 2

Leqembi

Eisai

Phase 3

7 3

Nuplazid

AACADIA Pharmaceuticals Inc.

Ozempic

3 5

Qalsody

Biogen

Phase 3

1 6

Namenda

AbbVie

Phase 2

2 7

Briviact

UCB

Phase 2

1 8

Leukine

Sanofi

Phase 2

1 9

Niacor

AbbVie

Phase 2

1 10

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Not yet recruiting

Alzheimer's Disease

NCT07768592

Clinical

Trials by Indication[1]

Elderly Participants1 trial

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

Completed· Eisai logo

Eisai·Phase 1·NCT05147337·47 enrolled

ART1 trial

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

Completed· Eisai logo

Eisai·Phase 1·NCT04547361·45 enrolled

Alzheimer's Disease1 trial

A Proof-of-Mechanism, Open-Label, Parallel Group Study With an Open-Label Extension Phase to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease

Not yet recruiting· Eisai logo

Eisai·Phase 1·NCT07768592·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for E2511. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E2511 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E2511. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eisai

E2511

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Elderly Participants1 trial

ART1 trial

Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News